Stay updated on ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page.

Latest updates to the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new revision label 'Revision: v3.4.2' is shown and the older operating-status notice (v3.4.1) has been removed; these are maintenance updates and do not modify the study details.SummaryDifference0.5%

- Check20 days agoChange DetectedThe update adds a government funding notice at the top and updates the page revision from v3.4.0 to v3.4.1, neither of which changes the study data or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded a 'Show glossary' option and updated metadata labels, including capitalization changes to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and introduced a new 'Revision: v3.4.0' entry.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. The page content and study details appear unchanged.SummaryDifference0.1%

- Check63 days agoChange DetectedAdds a Locations section listing participating sites in Illinois, Michigan, North Carolina, Ohio, Oregon, Pennsylvania, and South Carolina, and updates the page revision to v3.3.3.SummaryDifference1.0%

- Check91 days agoChange DetectedThe page now shows a new revision label v3.3.2, and the previous v3.2.0 label has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page.